# 2026-06063: FDA Tunes In to Patients: Drugs Now Reflect What We Want

2026-06063, Incorporating Voluntary Patient Preference Information Over the Total Product Life Cycle; Guidance for Industry, Food and Drug Administration Staff, and Other Interested Parties; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-30, effective 2026-03-30 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-06063
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-06063
- Title: Incorporating Voluntary Patient Preference Information Over the Total Product Life Cycle; Guidance for Industry, Food and Drug Administration Staff, and Other Interested Parties; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 15622
- Published: 2026-03-30
- Effective: 2026-03-30
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Tunes In to Patients: Drugs Now Reflect What We Want

## Summary

The FDA just dropped new guidance to help drug and device makers include patient preferences when developing and reviewing medical products. This means patients’ voices will play a bigger role from early testing to final approval, making treatments more in tune with what people really want. Companies should start using this advice now to improve their products and speed up FDA decisions, potentially saving time and money.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled "Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle." Patients provide valuable input to FDA in a variety of forms. This guidance describes the principles and concepts that FDA recommends sponsors and other interested parties consider when collecting and submitting patient preference information (PPI), discusses FDA's inclusion of PPI in its decision summaries, and provides recommendations for the inclusion of such information in device labeling for certain devices. PPI can be used in FDA decision making across the total product life cycle, including during review of investigational device exemption (IDE) applications, requests for a Breakthrough Device designation, premarket approval (PMA) applications, humanitarian device exemption (HDE) applications, De Novo classification requests, premarket notifications (510(k)s), or for FDA decisions involving administrative, enforcement, or other actions.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-06063 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/30/2026-06063/incorporating-voluntary-patient-preference-information-over-the-total-product-life-cycle-guidance)
- [2026-06063 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-30/pdf/2026-06063.pdf)

## Related
- [Previous: 2026-06062, Agency Information Collection Activities: Senior Farmers' Market Nutrition Prog…](https://policyrisk.com/federal-register/2026-06062)
- [Next: 2026-06065, Agency Information Collection Activities: Requests for Comments; Clearance of a…](https://policyrisk.com/federal-register/2026-06065)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-06063 (as of 2026-06-08).